Patient and Provider Fact Sheets
- Casirivimab/Imdevimab
- Bamlanivimab/Etesevimab
- Sotrovimab
- Evusheld
- Paxlovid
-
- Fact Sheet for Healthcare Providers (PDF)
- Fact Sheet for Patients, Parents and Caregivers (PDF) | Spanish
- Frequently Asked Questions on the Emergency Use Authorization for Paxlovid (PDF)
- Emergency Use Authorization (EUA) 105 Paxlovid Letter of Authorization (PDF)
- Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19 (PDF)
- Molnupiravir
- Bebtelovimab
Clinical Resources and Information
- COVID-19 therapeutics decision aid (PDF) (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Side-by-side overview of mAb therapeutics (ASPR)
- What's new in treatment guidelines (National Institutes of Health)
Guidance for Health Care Providers
State Resources
- Overview of WA State Order Process for COVID-19 Therapeutics (PDF)
- Interim Guidance on Monoclonal Antibody Use in Washington (PDF)
- PREP Act Authorization for Hospital Distribution of Antivirals (PDF) (1/4/2022)
- Interim DOH Guidance on Prioritization for Use of Molnupiravir (PDF)
- Interim DOH Guidance on Prioritization for Use of Paxlovid (PDF)
- Interim DOH Guidance on Prioritization for Use of EVUSHELD™ (PDF)
- Apple Health (Medicaid) monoclonal antibody treatment for COVID-19 clinical policy (PDF) (Health Care Authority)
Federal Resources
- Claims Reimbursement to Providers and Facilities - Frequently Asked Questions (Health Resources & Services Administration)
- General mAb information for providers (U.S. Department of Health and Human Services)
- Subcutaneous administration factsheet (PDF) (U.S. Department of Health and Human Services)
- Administrating mAbs checklist (PDF) (U.S. Department of Health and Human Services)
- Federal response playbook (PDF) (U.S. Department of Health and Human Services)
- Medicare reimbursement information (U.S. Centers for Medicare & Medicaid Services)
- Educational videos on monoclonal antibodies, including lessons learned, provider experiences, events and administering mAbs in your facility (U.S. Department of Health and Human Services)
- HRSA Health Center COVID-19 Therapeutics Program Participants (Health Resources & Services Administration)
- Uninsured Program Fact Sheet (PDF) (Health Resources & Services Administration)
- Statement on Patient Prioritization for Outpatient Therapies (National Institutes of Health)
Literature
- Intramuscular AZD7442 (Tixagevimab– Cilgavimab) for Prevention of Covid-19 (The New England Journal of Medicine)
- Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies (BioRxiv)
- Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages (BioRxiv)
- Will a rising Omicron variant scramble antibody treatments? (Nature)
- Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant (Mayo Clinic Proceedings)
- Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies (Biochimie)
- Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients (Transplant Infectious Disease Journal)
- The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials (Journal of Immunopharmacology and Immunotoxicology)
- Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system (Journal of Infection and Chemotherapy)
- Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents (Journal of The Pediatric Infectious Disease Society)
- Realizing the Potential of Anti–SARS-CoV-2Monoclonal Antibodies for COVID-19 Management (Rajesh T. Gandhi, MD, Massachusetts General Hospital)
- Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility—Arizona, 2021 (Journal of The American Geriatrics Society)
- Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities (The Journal of Infectious Diseases)
- Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use (The New England Journal of Medicine)
- Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians (Infectious Diseases Society of America)
- Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave (MedRxiv)
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 (The New England Journal of Medicine)
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study (MedRxiv)
- As reports of ‘Paxlovid rebound’ increase, Covid researchers scramble for answers (STAT)
- Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients (Oxford Academic)
- Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies (The Lancet)
- Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro (BioRxiv)
- The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir (BioRxiv)
- Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability- United States, December, 23 2021- May 21, 2022 (CDC)
- Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment- California, December 2021-May 2022 (CDC)